Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bearish -15

Amundi Reduces Holdings in Moderna, Inc. $MRNA - Defense World

📉 Amundi lowered its Moderna position by 20.9% in Q1, selling 238,790 shares while retaining a stake worth $45.96 million.

📊 Institutional ownership remains high at 75.33%, with smaller firms like MUFG and Flagship Harbor establishing new positions.

💰 Moderna beat Q1 revenue estimates of $102.93 million with actual sales reaching $145.00 million, a 2.1% year-over-year increase.

📉 The company reported a loss of $1.97 per share, missing the consensus expectation of a slightly larger loss at -$2.03.

🎯 Analyst consensus target price is set at $40.00 with an average rating of 'Reduce' based on data from MarketBeat.

📈 Goldman Sachs raised its price objective to $67.00, while Piper Sandler increased theirs to $77.00 with an 'overweight' rating.

📉 Wolfe Research maintained an 'underperform' rating with a lower target price of $25.00 for the stock.

💼 President Stephen Hoge sold 53,336 shares worth $2.74 million under a pre-arranged trading plan on June 15th.

📉 Corporate insider ownership stands at 10.80% following recent sales by executives to cover tax withholding obligations.

📈 Moderna's stock trades at a market cap of $21.75 billion with a negative P/E ratio of -6.86 due to ongoing losses.

📉 The stock is currently trading below its 50-day moving average of $59.37 and 200-day moving average of $52.64.

🔬 Moderna's flagship mRNA-based COVID-19 vaccine remains the primary revenue driver for the biotechnology company.

Bullish Signals
  • Moderna beat Q1 analyst revenue estimates, reporting $145.00 million in revenue against a consensus of $102.93 million.
  • Goldman Sachs Group lifted its price objective on Moderna from $49.00 to $67.00 while maintaining a neutral rating.
  • Piper Sandler increased its price target to $77.00 and upgraded the rating to 'overweight' in late June.
  • Moderna achieved revenue growth of 2.1% compared to the same quarter in the prior year.
Risk Factors
  • Wolfe Research reiterated an 'underperform' rating with a price target of $25.00, significantly below current levels.
  • The company reported a loss of $1.97 per share for the quarter, indicating continued financial losses despite revenue growth.
  • Analyst consensus targets the stock at $40.00 with an average rating of 'Reduce', suggesting limited near-term upside.
  • President Stephen Hoge sold 53,336 shares worth over $2.7 million, reducing his personal stake by 3.47%.
Full Analysis
Amundi reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 20.9% during the first quarter, selling 238,790 shares to retain a position valued at approximately $45.96 million. While Amundi decreased its stake, other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors established new positions, though their stakes remain relatively small compared to major funds. Overall, institutional ownership stands at 75.33% of the company's stock. Analyst sentiment remains mixed with a consensus target price of $40.00, reflecting a 'Reduce' average rating. While Goldman Sachs and Piper Sandler raised their price objectives to $67.00 and $77.00 respectively, Wolfe Research reiterated an 'underperform' rating with a $25.00 target. Morgan Stanley adjusted its target to $39.00 with an 'equal weight' rating, highlighting the divergence in market expectations for the biotech firm. Moderna reported quarterly earnings on July 31st, beating analyst estimates with revenue of $145.00 million compared to a consensus of $102.93 million. Despite the revenue beat, the company posted a loss of $1.97 per share versus an expected loss of $2.03, resulting in a negative net margin of 141.43%. Revenue grew by 2.1% year-over-year, but analysts expect continued losses with a projected annual earnings per share of -$6.41 for the current fiscal year. Insider trading activity shows President Stephen Hoge sold 53,336 shares worth approximately $2.74 million under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 3.47%. Other insiders also executed sales to cover tax obligations, with corporate insider ownership currently at 10.80%. The stock trades at a market cap of $21.75 billion with a P/E ratio of -6.86, trading below its 50-day moving average of $59.37.